The Technical Analyst
ImmunoGen Inc [IMGN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
ImmunoGen Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.02% $31.24
America/New_York / 9 feb 2024 @ 15:58
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 8 725.62 mill |
| EPS: | -0.280 |
| P/E: | -111.55 |
| Earnings Date: | Feb 28, 2024 |
| SharesOutstanding: | 279.35 mill |
| Avg Daily Volume: | 8.29 mill |
| RATING 2024-02-09 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -111.55 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -18.98x |
| Company: PE -111.55 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 30.92 - 31.54 ( +/- 0.98%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-12 | Mitchell Dean J | Sell | 103 000 | Common Stock |
| 2024-02-12 | Mitchell Dean J | Sell | 13 090 | Restricted Stock Unit |
| 2024-02-12 | Mitchell Dean J | Sell | 142 667 | Deferred Share Unit |
| 2024-02-12 | Mitchell Dean J | Sell | 10 000 | Stock Option (Right to Buy) |
| 2024-02-12 | Mitchell Dean J | Sell | 10 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| -100.00 |
| Last 100 transactions |
| Buy: 0 | Sell: 8 781 240 |
Forecast:
01:40 - $33.55
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $31.24 (0.02% ) |
| Volume | 19.31 mill |
| Avg. Vol. | 8.29 mill |
| % of Avg. Vol | 233.01 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IMGN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $31.23 | N/A | Active |
|---|
IMGN
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Latest Press Releases
2024-02-12 07:37:00 - Press Release
Abbvie Completes Acquisition Of Immunogen
Adds flagship antibody-drug conjugate (adc) elahere® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (frΑ) positive platinum-resistant ovarian cancer (proc) to abbvie's portfolio immunogen's pipeline complements abbvie's existing oncology pipeline with potential to be transformative across multiple solid tumors and hematologic malignancies immunogen's late-stage development programs for elahere provide opportunity to expand into earlier lines of therapy and additional patient populations abbvie reaffirms previously issued 2024 full-year adjusted diluted eps guidance range of $11.05-$11.25 which now includes a $0.42 per share dilutive impact related to the immunogen acquisition and the pending cerevel therapeutics acquisition abbvie updates previously issued 2024 first-quarter adjusted diluted eps guidance range from $2...
2024-02-01 16:30:00 - Press Release
Immunogen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Waltham, mass.--(business wire)--immunogen announces inducement grants under nasdaq listing rule 5635(c)(4).
2024-01-03 16:30:00 - Press Release
Immunogen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Waltham, mass.--(business wire)--immunogen announces inducement grants under nasdaq listing rule 5635(c)(4).
2023-12-10 12:00:00 - Press Release
Immunogen Presents Findings From Newly Diagnosed Acute Myeloid Leukemia Cohorts In Phase 1b/2 Study Of Pivekimab Sunirine In Combination With Azacitidine And Venetoclax At Ash
Waltham, mass.--(business wire)--immunogen presents findings from newly diagnosed aml cohorts in phase 1b/2 study of pivekimab sunirine with azacitidine and venetoclax at ash.
2023-12-05 06:30:00 - Press Release
Fda Grants Priority Review Of Immunogen's Supplemental Biologics License Application For Elahere® (mirvetuximab Soravtansine-gynx) In Platinum-resistant Ovarian Cancer
Waltham, mass.--(business wire)--immunogen, inc. (nasdaq: imgn), a leader in the expanding field of antibody-drug conjugates (adcs) for the treatment of cancer, today announced that the us food and drug administration (fda) has filed the supplemental biologics license application (sbla) supporting the conversion of the accelerated approval of elahere® (mirvetuximab soravtansine-gynx) for the treatment of patients with folate receptor alpha (frΑ)-positive, platinum-resistant epithelial ovarian,.
Latest News
2024-02-12 12:20:52 - Investopedia
AbbVie Cuts Its Guidance on ImmunoGen Deal
Drug maker AbbVie (ABBV) is lowering its current quarter guidance because of costs related to its acquisition of ImmunoGen.
2024-02-12 07:51:00 - Market Watch
AbbVie's stock dips premarket after it lowers Q1 guidance to reflect dilutive impact of ImmunoGen deal close
AbbVie Inc.'s stock ABBV, -0.41% fell 0.5% early Monday, after the drug company lowered its first-quarter guidance to reflect the dilutive impact of its closure of the acquisition of ImmunoGen. The company said it now expects first-quarter per-share earnings to range from $2.26 to $2.30, down from prior guidance of $2.30 to $2.34, including a 4 cent per share dilutive impact from the Immunogen deal.
2024-02-09 10:40:25 - Zacks Investment Research
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?
Here is how ImmunoGen (IMGN) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
2024-02-09 07:01:07 - Zacks Investment Research
ImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?
ImmunoGen (IMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2024-02-06 14:38:48 - InvestorPlace
7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024
As 2023 wrapped up, Russell 2000 stocks, mirroring the dynamics of small-to-mid-cap companies, showed resilience, outperforming their initial stance. The iShares Russell 2000 ETF (NYSEARCA: IWM ), a key barometer for these stocks, boasts over $60 billion in assets and a robust daily trading volume surpassing 40 million, setting an impressive stage for these agile market players.
2024-01-09 09:01:16 - Zacks Investment Research
How ImmunoGen (IMGN) Stock Stands Out in a Strong Industry
ImmunoGen (IMGN) has seen solid earnings estimate revision activity over the past two month, and belongs to a strong industry as well.
2024-01-04 13:32:26 - Zacks Investment Research
All You Need to Know About ImmunoGen (IMGN) Rating Upgrade to Strong Buy
ImmunoGen (IMGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
2024-01-04 08:17:13 - Zacks Investment Research
New Strong Buy Stocks for January 4th
IMGN, GTLB, FNWD, BL and TMHC have been added to the Zacks Rank #1 (Strong Buy) List on January 4, 2024.
2023-12-26 08:30:00 - The Motley Fool
AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why
AbbVie needs to diversify its drug portfolio because of the loss of exclusive rights to Humira. The recent acquisition of ImmunoGen fills several needs and comes at an excellent time.
2023-12-25 20:23:09 - InvestorPlace
3 Stocks at the Forefront of Medical Innovation
Innovation in the medical world is undoubtedly a fundamental pillar in the development of humanity. There are great companies within the biotech sector doing wonderful work, research, and developments, not only to attack important diseases but also to prevent them.